Pierre-Eric Juif

8PUBLICATIONS
21CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyClinical pharmacology and therapeuticsCancer therapy (excl. chemotherapy and radiation therapy)Characterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 15, 2025
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.

Marc S Raab, Yael C Cohen, Fredrik Schjesvold

|Nov 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.

Todd M Bauer, Armando Santoro, Chia-Chi Lin

|Apr 06, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.

Marc S Raab, Yael C Cohen, Fredrik Schjesvold

|Jan 07, 2021
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.

Uta Schilling, Jasper Dingemanse, Michael Dobrow

|Jan 03, 2021
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.

Andrea Henrich, Pierre-Eric Juif, Jasper Dingemanse

|Aug 30, 2020
Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P<sub>1</sub> R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects.

Pierre-Eric Juif, Jasper Dingemanse, Peter Winkle

Pageof 2

Frequent Collaborators

3 joint publications

Jasper Dingemanse

2 joint publications

Jonathan L Kaufman

2 joint publications

Andreas Krause

2 joint publications

Anita D Souza